Christopher A. Yasenchak, MD, discusses the safety profile of brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.
Christopher A. Yasenchak, MD
Advertisement
Articles by Christopher A. Yasenchak, MD
Christopher A. Yasenchak, MD, discusses brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.
Christopher A. Yasenchak, MD, associate chair of Hematology Research, Willamette Valley Cancer Institute and Research Center/US Oncology Research, discusses results of a study examining the addition of brentuximab vedotin to R-CHOP for the treatment of patients with diffuse large B-cell lymphoma.
Advertisement
Latest Updated Articles
Dr. Yasenchak on Brentuximb Vedotin Plus Nivolumab in Hodgkin LymphomaPublished: January 24th 2020 | Updated:
Dr. Yasenchak on the Safety Profile of Brentuximab Vedotin/Nivolumab in Hodgkin LymphomaPublished: May 9th 2020 | Updated:
Dr. Yasenchak on Brentuximab Vedotin Added to R-CHOP in DLBCLPublished: February 17th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5